Bioline Rx Profit Margin

The latest profit margin for BLRX is -1.21% as of March 2026. That compares with -31.86% in the prior-year period — down 278.8% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Bioline Rx's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLRX's profit margin moved from -31.86% to -1.21% — a 278.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bioline Rx's valuation or profitability profile.

Against Healthcare companies, BLRX currently prints -1.21% for profit margin, while the sector average sits near 15.58%. That is roughly 874.4% below the sector mean. Large gaps often invite a closer look at Bioline Rx's growth, margins, and balance sheet.

Profit Margin shows how effectively Bioline Rx converts resources into returns. At -1.21%, BLRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -31.86% in the prior-year period — down 278.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BLRX's profit margin (-1.21%), review year-over-year change from -31.86%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.